Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial | Zendy

AI Assistant Blog Pricing

Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.